Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM15HL8)

Drug Name
Clindamycin Drug Info
Synonyms
Antirobe; CLDM; CLY; Chlolincocin; Chlorlincocin; Chlorodeoxylincomycin; Chlorolincomycin; Cleocin; ClindaDerm; Clindamicina; Clindamycine; Clindamycinum; Clinimycin; Dalacine; Klimicin; Sobelin; Zindaclin; Cleocin HCl; Cleocin T Gel; Cleocin T Lotion; Cleocin T Topical Solution; Clindamycine [French]; Dalacin C; Dalacin C Flavored Granules; Dalacin C Phosphate; Dalacin T Topical Solution; ResiDerm A; Klindan 300; U 21251; Cleocin (TN); Clindacin (TN); Clindamicina [INN-Spanish]; Clindamycin & Interleukin 12; Clindamycin & VRC3375; Clindamycine [INN-French]; Clindamycinum [INN-Latin]; Dalacin (TN); Evoclin (TN); U-21251; CLINDA & IL-12; Clindamycin (USAN/INN); Clindamycin [USAN:BAN:INN]; U-21,251; 7(S)-Chloro-7-deoxylincomycin; 7-CDL; 7-Chloro-7-deoxylincomycin; 7-Chlorolincomycin; 7-Deoxy-7(S)-chlorolincomycin
Therapeutic ClassAntibiotics
Cross-matching ID
PubChem CID
446598
ChEBI ID
CHEMBL1753
CAS Number
CAS 18323-44-9
TTD Drug ID
D0R0ZL
VARIDT Drug ID
DR00972
INTEDE Drug ID
DR0340
ACDINA Drug ID
D00136

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.25 0.00e+0 34/36 (94.44%) PCNA;MCM5;MCM2;...
Proteasome 2.24 0.00e+0 44/46 (95.65%) PSMC3;PSMD14;PSMB1;...
Fc gamma R-mediated phagocytosis 2.01 0.00e+0 79/97 (81.44%) MARCKSL1;LYN;PIK3CA;...
Antigen processing and presentation 1.98 3.06e-3 60/78 (76.92%) HSPA8;HLA-B;HSPA4;...
Epstein-Barr virus infection 1.94 4.90e-3 189/202 (93.56%) HLA-B;PSMC3;LYN;...
Mismatch repair 1.91 6.13e-3 22/23 (95.65%) PCNA;POLD4;LIG1;...
Viral carcinogenesis 1.90 7.00e-3 149/203 (73.4%) PKM;HLA-B;RANBP1;...
Bacterial invasion of epithelial cells 1.89 7.66e-3 59/77 (76.62%) PIK3CA;ARPC1B;PXN;...
Viral myocarditis 1.89 6.81e-3 53/60 (88.33%) HLA-B;BID;HLA-C;...
Allograft rejection 1.87 8.58e-3 32/38 (84.21%) HLA-B;HLA-C;HLA-F;...
Spinocerebellar ataxia 1.84 1.00e-2 128/143 (89.51%) GRIA2;PSMC3;PIK3CA;...
Graft-versus-host disease 1.83 1.02e-2 32/42 (76.19%) HLA-B;HLA-C;HLA-F;...
Oocyte meiosis 1.83 9.43e-3 90/129 (69.77%) CDC20;ADCY1;PLK1;...
Galactose metabolism 1.82 9.63e-3 26/31 (83.87%) PFKP;HK2;AKR1B1;...
Progesterone-mediated oocyte maturation 1.80 1.55e-2 75/100 (75%) ADCY1;PLK1;PIK3CA;...
Autoimmune thyroid disease 1.78 1.76e-2 46/53 (86.79%) HLA-B;HLA-C;HLA-F;...
Pyrimidine metabolism 1.77 1.66e-2 40/56 (71.43%) TYMS;RRM1;RRM2;...
Cell cycle 1.72 2.79e-2 110/124 (88.71%) PCNA;CDKN1C;TGFB1;...
Herpes simplex virus 1 infection 1.71 2.77e-2 165/498 (33.13%) HLA-B;C3;PIK3CA;...
N-Glycan biosynthesis 1.69 3.43e-2 38/50 (76%) MAN2A1;MAN1C1;GANAB;...
Folate biosynthesis 1.68 3.38e-2 23/26 (88.46%) AKR1C3;AKR1B1;DHFR;...
Starch and sucrose metabolism 1.66 4.74e-2 25/36 (69.44%) GPI;HK2;GYG1;...
Fructose and mannose metabolism 1.65 4.58e-2 30/33 (90.91%) PFKP;HK2;PFKFB3;...
Type I diabetes mellitus 1.65 4.49e-2 38/43 (88.37%) HLA-B;HLA-C;HLA-F;...
Viral protein interaction with cytokine and cytokine re... -1.77 2.64e-2 84/100 (84%) CCR5;CXCL11;PF4;...
Rheumatoid arthritis -1.80 2.38e-2 78/93 (83.87%) CSF1;ATP6V0A1;CCL20;...
Terpenoid backbone biosynthesis -1.86 1.47e-2 18/22 (81.82%) ACAT2;HMGCR;HMGCS1;...
IL-17 signaling pathway -2.02 3.67e-3 84/94 (89.36%) CXCL6;TNFAIP3;S100A7;...
Primary bile acid biosynthesis -2.04 7.34e-3 15/17 (88.24%) BAAT;CYP46A1;HSD17B4;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 4uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 8uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 2.22uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H